✦ LIBER ✦

Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open-label trial

✍ Scribed by D M Simon; S C Gordon; M M Kaplan; R S Koff; F Regenstein; G Everson; Y M Lee; F Weiner; A Silverman; T Plasse; D Fedorczyk; M Liao

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 217 KB
Volume: 25
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510250232

No coin nor oath required. For personal study only.

✦ Synopsis

We studied the antiviral effectiveness and safety of interferon alfa-n3, a natural alpha interferon which contains multiple interferon species, in the treatment of previously untreated patients with chronic hepatitis C. Seventy-seven patients were randomized to receive either 1.0, 2.5, 5.0, or 10.0 million units (MU) of interferon alfa-n3 three times a week for 24 weeks and were then followed for an additional 24 weeks. At the end of therapy, 67% of patients in the 10 MU group normalized serum alanine transaminase (ALT) levels and 59% had no hepatitis C virus (HCV) RNA detected by polymerase chain reaction. At the end of the follow-up period, 44% of patients in the 10 MU group maintained normal ALT, and 24% had nondetectable HCV RNA. Lower doses were much less effective. Interferon alfa-n3 was well tolerated and no patient developed neutralizing anti-interferon antibodies during or after the treatment period. Interferon alfa-n3 appears to be effective against hepatitis C virus and deserves further study in larger randomized controlled trials.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis C with co

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 1 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 1 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

Randomized trial comparing three differe

Randomized trial comparing three different regimens of interferon alfa 2a in chronic hepatitis C

✍ M Angelico 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

small numbers of HCC cells may be released into the man research review committee. Informed consent had been obtained from the patients involved. circulation, be it spontaneously or induced by surgical The results show that albumin mRNA can be demanipulation. Based on their findings, the authors su

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Better efficacy of a 12-month interferon

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial

✍ Jean-Louis Payen; Jacques Izopet; Virginie Galindo-Migeot; Valérie Lauwers-Cance 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

We studied the efficacy of three interferon alfa-2b (IFN-2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse. Consecutive patients with CHC who had a complete biochemical response but relapse after a first course of 6 months of

Lymphoblastoid interferon alfa with or w

Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial

✍ G V Gregorio; P Jara; L Hierro; C Diaz; A de la Vega; A Vegnente; R Iorio; F Bor 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 1 views

## Steroid priming does not potentiate the effect of IFN-a. The comparative efficacy of prednisolone followed by (HEPATOLOGY 1996;23:700-707.) interferon alfa (IFN-a) versus IFN-a alone in enhancing the rate of antibody to hepatitis B e antigen (anti-HBe) seroconversion has not been evaluated in a